Innocoll, which develops and markets collagen-based products to treat adhesions, pain and foot infections filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The company lists Morgan Stanley (NYSE: MS) among its investors, with a 24% pre-IPO stake.
The Athlone, Ireland-based company, which was founded in 1997 and booked $5 million in sales for the 12 months ended March 31 2014, plans to list on the NASDAQ under the symbol INNL. Innocoll initially filed confidentially on March 26, 2014. Piper Jaffray and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
